Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

BACKGROUND: Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and may limit disease progression and com...

Descripción completa

Detalles Bibliográficos
Autores principales: Dougan, Michael, Nirula, Ajay, Azizad, Masoud, Mocherla, Bharat, Gottlieb, Robert L., Chen, Peter, Hebert, Corey, Perry, Russell, Boscia, Joseph, Heller, Barry, Morris, Jason, Crystal, Chad, Igbinadolor, Awawu, Huhn, Gregory, Cardona, Jose, Shawa, Imad, Kumar, Princy, Adams, Andrew C., Van Naarden, Jacob, Custer, Kenneth L., Durante, Michael, Oakley, Gerard, Schade, Andrew E., Holzer, Timothy R., Ebert, Philip J., Higgs, Richard E., Kallewaard, Nicole L., Sabo, Janelle, Patel, Dipak R., Dabora, Matan C., Klekotka, Paul, Shen, Lei, Skovronsky, Daniel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314785/
https://www.ncbi.nlm.nih.gov/pubmed/34260849
http://dx.doi.org/10.1056/NEJMoa2102685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314785/
https://www.ncbi.nlm.nih.gov/pubmed/34260849
http://dx.doi.org/10.1056/NEJMoa2102685

Ejemplares similares